Related Experiment Video
Updated: Jul 12, 2026
07:03
Large Scale Zebrafish-Based In vivo Small Molecule Screen
Published on: December 30, 2010
Phenotypic screening for small molecules that lower PrP in cultured cells
Jeannine A Frei1, Andrew G Reidenbach1, Leo M H Xu1
1Program in Brain Health, Broad Institute of MIT and Harvard, Cambridge, MA, 02142, USA.
Molecular and Cellular Neurosciences
|July 9, 2026
Summary
Researchers screened compounds to lower prion protein (PrP) for prion disease therapy. Two molecules, EYH and LCZ, selectively reduced PrP via proteasome degradation, but showed limited efficacy in human cells and in vivo.
Area of Science:
- Neuroscience
- Pharmacology
- Molecular Biology
Background:
- Prion protein (PrP) lowering is a therapeutic strategy for prion diseases.
- Phenotypic screening is a method to identify bioactive compounds.
Purpose of the Study:
- To identify small molecules that selectively lower prion protein (PrP) levels.
- To investigate the mechanism of PrP reduction by identified compounds.
Main Methods:
- Phenotypic screening of 3492 compounds using GFP-expressing mouse N2a cells.
- High-content imaging analysis for PrP and GFP levels and cell viability.
- Proteomics to assess global protein changes.
- Assays to evaluate Prnp mRNA levels and PrP expression in different cell types and in vivo.
Main Results:
- Two compounds, EYH and LCZ, selectively and dose-dependently lowered PrP levels.
- Proteomics identified PrP as a top downregulated protein; compounds acted post-translationally via proteasome degradation.
- Compounds showed limited activity in human cell lines and failed to reduce PrP in vivo after 14 days.
Conclusions:
- Mechanism-agnostic screening identified potential PrP-lowering agents.
- Challenges exist in translating in vitro findings to in vivo efficacy for PrP reduction.
- Prioritizing compounds with known mechanisms may be more effective for therapeutic development.
